GlassScriptPhysician profile
Andrew Eric Brookens
NPI 1396035341
$1,713.50
in general payments reported to CMS, 2019-2025
19 companies · $545 in 2025
The $545 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $16.84 · 2021: $355 · 2022: $51.77 · 2023: $281 · 2024: $275 · 2025: $545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,079 · Education: $21.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,079.17 |
| Education | $21.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $240.66 | 2021-2025 | |
| Amgen INC. | $219.02 | 2020-2025 | Krystexxa, Tavneos |
| Nxstage Medical, INC. | $197.38 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $183.05 | 2019-2025 | Lokelma |
| Novartis Pharmaceuticals Corporation | $168.16 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $140.63 | 2019-2025 | Jynarque, Voyxact |
| Horizon Therapeutics Plc | $97.53 | 2021-2023 | Krystexxa |
| Novo Nordisk INC | $86.10 | 2025 | Ozempic, Rivfloza |
| Calliditas Therapeutics US INC. | $85.97 | 2024-2025 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.83 | 2025 | Jardiance |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $46.95 | 2024-2025 | Jynarque |
| Alexion Pharmaceuticals, INC. | $42.03 | 2024-2025 | Ultomiris |
| Glaxosmithkline, LLC. | $40.76 | 2021 | |
| Baxter Healthcare | $26.88 | 2021 | |
| Merck Sharp & Dohme LLC | $25.62 | 2025 | Prevymis |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $20.61 | 2025 | |
| Aurinia Pharma U.S., INC. | $14.85 | 2022 | |
| Daiichi Sankyo INC. | $14.81 | 2023 | Injectafer |
| Travere Therapeutics, INC. | $1.66 | 2025 | Filspari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Brookens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.